MOR vs. QGEN, MRNA, ASND, VTRS, BBIO, VRNA, BPMC, ROIV, GRFS, and LEGN
Should you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.
MorphoSys vs. Its Competitors
MorphoSys (NASDAQ:MOR) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.
MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
In the previous week, Qiagen had 16 more articles in the media than MorphoSys. MarketBeat recorded 16 mentions for Qiagen and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 1.08 beat Qiagen's score of 0.77 indicating that MorphoSys is being referred to more favorably in the media.
Qiagen has a consensus target price of $49.69, suggesting a potential upside of 0.61%. Given Qiagen's stronger consensus rating and higher probable upside, analysts clearly believe Qiagen is more favorable than MorphoSys.
Qiagen has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Qiagen has a net margin of 18.30% compared to MorphoSys' net margin of -226.79%. Qiagen's return on equity of 14.77% beat MorphoSys' return on equity.
Summary
Qiagen beats MorphoSys on 13 of the 16 factors compared between the two stocks.
Get MorphoSys News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MorphoSys Competitors List
Related Companies and Tools
This page (NASDAQ:MOR) was last updated on 8/15/2025 by MarketBeat.com Staff
MarketBeat All Access